1. Home
  2. JFIN vs NRIX Comparison

JFIN vs NRIX Comparison

Compare JFIN & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JFIN
  • NRIX
  • Stock Information
  • Founded
  • JFIN 2011
  • NRIX 2009
  • Country
  • JFIN China
  • NRIX United States
  • Employees
  • JFIN N/A
  • NRIX N/A
  • Industry
  • JFIN Finance: Consumer Services
  • NRIX Biotechnology: Pharmaceutical Preparations
  • Sector
  • JFIN Finance
  • NRIX Health Care
  • Exchange
  • JFIN Nasdaq
  • NRIX Nasdaq
  • Market Cap
  • JFIN 682.1M
  • NRIX 728.6M
  • IPO Year
  • JFIN 2019
  • NRIX 2020
  • Fundamental
  • Price
  • JFIN $11.60
  • NRIX $8.91
  • Analyst Decision
  • JFIN
  • NRIX Strong Buy
  • Analyst Count
  • JFIN 0
  • NRIX 14
  • Target Price
  • JFIN N/A
  • NRIX $29.07
  • AVG Volume (30 Days)
  • JFIN 140.3K
  • NRIX 761.7K
  • Earning Date
  • JFIN 08-20-2025
  • NRIX 10-10-2025
  • Dividend Yield
  • JFIN 7.33%
  • NRIX N/A
  • EPS Growth
  • JFIN 33.85
  • NRIX N/A
  • EPS
  • JFIN 4.21
  • NRIX N/A
  • Revenue
  • JFIN $908,895,698.00
  • NRIX $88,381,000.00
  • Revenue This Year
  • JFIN N/A
  • NRIX $74.59
  • Revenue Next Year
  • JFIN N/A
  • NRIX N/A
  • P/E Ratio
  • JFIN $2.60
  • NRIX N/A
  • Revenue Growth
  • JFIN 8.19
  • NRIX 41.86
  • 52 Week Low
  • JFIN $5.18
  • NRIX $8.18
  • 52 Week High
  • JFIN $19.23
  • NRIX $29.56
  • Technical
  • Relative Strength Index (RSI)
  • JFIN 50.05
  • NRIX 51.13
  • Support Level
  • JFIN N/A
  • NRIX $8.90
  • Resistance Level
  • JFIN $11.42
  • NRIX $10.13
  • Average True Range (ATR)
  • JFIN 0.63
  • NRIX 0.43
  • MACD
  • JFIN -0.40
  • NRIX -0.47
  • Stochastic Oscillator
  • JFIN 84.98
  • NRIX 87.96

About JFIN Jiayin Group Inc.

Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Share on Social Networks: